Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer
Mené dans 30 pays sur 780 patients atteints d'un cancer de l'estomac ou de la jonction œsogastrique HER2+ de stade métastatique, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout du pertuzumab à un traitement de première ligne combinant trastuzumab et chimiothérapie (durée médiane de suivi : 25 mois)
In The Lancet Oncology, Josep Tabernero and colleagues report the final analysis of the JACOB trial, which tested the efficacy and safety of pertuzumab (a monoclonal antibody targeting HER2 receptors) combined with trastuzumab and chemotherapy in previously untreated patients with HER2-positive metastatic gastric or gastro-oesophageal junction cancer. JACOB was the first trial to investigate a dual HER2 blockade in metastatic gastric cancer; unfortunately, no significant improvement in overall survival was observed in the group treated with the dual-HER2 targeted combination.
The Lancet Oncology , commentaire, 2017